Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI
NCT ID: NCT04856059
Last Updated: 2023-07-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
250 participants
INTERVENTIONAL
2021-06-15
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improved Detection of Myocardial Fibrosis: a Cardiovascular Magnetic Resonance Imaging Study
NCT06697509
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
NCT06409585
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease
NCT06776419
Myocardial Fibrosis, Function and Aging
NCT03064503
T1 Mapping of Diffuse Myocardial Fibrosis in Congenital Heart Disease
NCT02350829
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
It is hypothesized that new cardiac MRI techniques called T1 and T2 mapping will improve the ability to detect early abnormalities in the heart. Early detection of cardiac disease may enable a personalized treatment approach, potentially improving patient outcomes. The results of the study will identify which patients might benefit from early initiation of treatment to prevent bad outcomes in the future by using cardiac MRI to identify those at higher risk.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cardiac MRI, ECG and Blood Biomarkers
Additional sequences will be performed during routine clinical cardiac MRI and additional blood samples will be collected during routine blood work.
Cardiac MRI, ECG/Holter and Blood Biomarkers
Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cardiac MRI, ECG/Holter and Blood Biomarkers
Cardiac MRI including T1/T2 mapping, ECG and blood biomarker evaluation will be performed at baseline and follow-up
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age ≥ 18 years.
Exclusion Criteria
* Contraindication to MRI.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vancouver General Hospital
OTHER
The Cleveland Clinic
OTHER
Icahn School of Medicine at Mount Sinai
OTHER
Mayo Clinic
OTHER
University of Colorado, Denver
OTHER
IRCCS Policlinico S. Donato
OTHER
Alberta Health services
OTHER
Libin Cardiovascular Institute of Alberta
OTHER
University Health Network, Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kate Hanneman
Role: PRINCIPAL_INVESTIGATOR
University Health Network, Toronto
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Health Network
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-5167
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.